Attacking Leukemia Resistance
Chronic myeloid leukemia ( CML ) is a tricky cancer because it can respond well to initial therapy, but then that drug sometimes stops working. The same thing can happen when different – second-line – drugs are used. The reason for this is that the disease tends to keep changing or mutating.
New Chronic Myeloid Leukemia Drug
Chronic myeloid leukemia often responds to first-line treatment. Gleevec ( imatinib ) is the standard first-line medication. The disease usually quiets for a time, then comes back. A new drug has been approved to treat this blood and bone marrow cancer.
Young People with Chronic Myeloid Leukemia
Since targeted therapies known as tyrosine kinase inhibitors (TKI) have been in use, the outlook for people diagnosed with chronic myeloid leukemia has improved dramatically. Unfortunately, this trend isn't true for all patients.
With CML, Third Time Can Be a Charm
The course of chronic myeloid leukemia (CML) has changed substantially thanks to the use of a class of drugs called tyrosine kinase inhibitors (TKIs). How these drugs are being used is changing too.
Outwitting Chronic Myeloid Leukemia
About 20 percent of all leukemias in the Western world are chronic myeloid leukemia ( CML ). Today's treatments target an abnormal chromosome that causes the disease, but new theories about how to outwit this resilient disease are sprouting.
Tasigna Recommended for Second-Line CML
Tasigna ( nilotinib ) is one of the three major medications currently being used to treat chronic myeloid leukemia ( CML ). Now it has become a preferred drug in one country.
Marathon Against CML Still Not Won
Remarkable advancements have been made in the treatment of chronic myeloid leukemia. But the race has not yet been won, according to one of the nation's preeminent experts in the field.
Waging War Against Chronic Myeloid Leukemia
A possible new front runner is emerging in the drug war against chronic myeloid leukemia ( CML ). While still considered experimental, this drug is showing itself to be a powerful agent against advanced forms of the disease.
Unlocking Chronic Myeloid Leukemia Resistance
Gleevec ( imatinib ) has transformed the treatment of chronic myeloid leukemia ( CML ). The problem is, this drug stops working at some point in many patients. A drug under development, combined with another currently available medication, may offer patients new options.
Improving Chronic Myeloid Leukemia Treatment
Since its introduction some years ago, Gleevec ( imatinib ) has been the drug of choice for treating patients newly diagnosed with chronic myeloid leukemia ( CML ).